Delivery Order SPE2DB22D1106-SPE2DB25FDYF0

Award Date 2/7/25
Potential Completion Date 2/10/25
Potential Value $1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract provides for the delivery of REFRESH PLUS 0.5% EYE DROPS UD 70S, a pharmaceutical product, with a ceiling value of $1,675.53 and a completion date of November 27, 2024. This is a firm fixed-price delivery order contract, and there was no set-aside designation used. AmerisourceBergen holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,976.37, is for the supply of "REFRESH PLUS 0.5% EYE DROPS 30S" medical products. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,093.43 firm fixed-price delivery order covers the supply of "REFRESH PLUS 0.5% EYE DROPS UD 50S" medical products. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of...
This federal contract award, valued at $1,929.59, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Refresh Plus 0.5% eye drops in 30-count packages, with a completion date of January 15, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical,...
This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of "REFRESH PLUS 0.5% EYE DROPS UD 50S" medical products. The $5,815.58 firm fixed-price delivery order has a completion date of May 29, 2024. The award is not designated under any set-aside program. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award, valued at $1,417.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order to provide "REFRESH PLUS 0.5% EYE DROPS 30S" for the DLA. It is a firm fixed-price contract with a completion date of May 17, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for $2,584.79. The contract is a Firm Fixed Price Delivery Order for the supply of "REFRESH PLUS 0.5% EYE DROPS 30S", a pharmaceutical product. The contract has an ultimate completion date of January 3, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,510.50 firm-fixed-price delivery order contract covers the supply of "REFRESH PLUS 0.5% EYE DROPS UD 50S", a medical commodity. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,255.01 Firm Fixed Price Delivery Order is for the supply of "REFRESH PLUS 0.5% EYE DROPS UD 50S" and has an ultimate completion date of May 31, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office division. The contract, valued at $1,840.32, is for the delivery of REFRESH PLUS 0.5% EYE DROPS 30S, a pharmaceutical product. The contract has an ultimate completion date of October 10, 2024 and is a firm-fixed-price delivery order. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple federal contracts and Indefinite Delivery Contracts...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB25FDYF0
    Delivery Order

This federal contract award, with ID SPE2DB22D1106 and SPE2DB25FDYF0, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,007.40, is for the delivery of "REFRESH PLUS 0.5% EYE DROPS 30S" and has a completion date of February 10, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Additionally, the company maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs. This contract award was not designated with a set-aside requirement, indicating open competition.

Generated 5/9/25, 10:05 AM